Jefferies analyst, David Steinberg, reiterated his Buy rating on shares of Supernus Pharmaceuticals (NASDAQ: SUPN) after hosting a day of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE